New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesamorelin vs Cagrilintide

Tesamorelin vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesFat Loss & Metabolic
Tesamorelin
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
~26 minutes
~7–10 days
Admin Route
SubQ
SubQ
Research
Typical Dose
2 mg
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
Once daily
Once weekly
Key Benefits
  • FDA-approved for visceral fat reduction in HIV lipodystrophy
  • Significant reduction in trunk/visceral fat (average 15–20% in trials)
  • Improved triglyceride and lipid profiles
  • Potential cognitive benefits and memory improvement
  • Preserves lean mass while reducing fat
  • Natural pulsatile GH stimulation
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Injection site reactions (redness, irritation)
  • Arthralgia and joint pain
  • Peripheral edema
  • Carpal tunnel syndrome
  • +2 more
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With